Scan.com Raises $90M in Series C+ to Expand US Imaging Network

Scan.com, a medical imaging network and API platform, has raised $90 million in a Series C+ funding round. The investment was led by Noteus Partners, with participation from Aviva Investors, Oxford Capital, Concord Health Partners, and YZR Capital. The round was announced on August 31, 2026.

Company Overview

Founded in London in 2021, Scan.com connects patients, referring clinicians, payers, and independent imaging centers across the US and UK. The platform matches each referral against live availability, price, and subspecialty, automating booking, prior authorization, and paperwork. Results are routed to subspecialist radiologists, with reports typically returned within 48 hours.

Scan.com is the UK's largest private medical imaging network and has operated nationwide in the US since 2023. The US is now its primary market, home to roughly 80% of its staff.

Funding Details

The Series C+ round brings new capital to support Scan.com's growth, particularly in the US market. The company plans to leverage the funding to expand its network and enhance its platform, though specific use-of-proceeds details were not disclosed.

Investor Confidence

The participation of both new and existing investors, including Noteus Partners as lead, signals confidence in Scan.com's model and market position. The company's ability to attract investment from a diverse group of financial backers underscores its potential in the medical imaging space.

About the Investors

• Noteus Partners: Lead investor in this round.
• Aviva Investors: A global asset management business.
• Oxford Capital: An investment firm focused on growth companies.
• Concord Health Partners: A healthcare-focused private equity firm.
• YZR Capital: An investment firm.

Outlook

With this new funding, Scan.com is well-positioned to continue its expansion and innovation in medical imaging. The company's focus on efficiency and quality, combined with its strong investor backing, suggests a promising trajectory ahead.